Discovering The Potential of Rpl23P6 as A Drug Target (G646949)

Target Name: RPL23P6

NCBI ID: G646949

RPL23P6

Other Name(s): RPL23_1_689 | Ribosomal protein L23 pseudogene 6 | ribosomal protein L23 pseudogene 6

Discovering The Potential of Rpl23P6 as A Drug Target

Rpl23P6 (RPL23_1_689) is a protein that is expressed in various tissues of the human body, including the brain, heart, and kidneys. It is a key regulator of the Replication Protein 23 (RPL23) complex, which is involved in the repair of damaged DNA in the cell. RPL23P6 has also been shown to play a role in the development and progression of various diseases, including cancer. As a result, Rpl23P6 has generated a lot of interest as a potential drug target or biomarker. In this article, we will discuss the biology and function of Rpl23P6, as well as its potential as a drug target.

History of Rpl23P6

The Replication Protein 23 (RPL23) complex is a protein complex that plays a critical role in the repair of damaged DNA in the cell. RPL23 is a protein that consists of two subunits, Rpl23A and Rpl23B. These subunits contain a domain that is similar to that of the protein X-linked imprinted transcription factor 1 (XISF1), as well as a catalytic domain and a N-terminus.

The RPL23 complex has been shown to play a role in the repair of damaged DNA in the cell. When the DNA is damaged, RPL23 is involved in the formation of a complex with the protein NGAT, which helps to repair the damage. RPL23P6 is a protein that is expressed in various tissues of the human body, including the brain, heart, and kidneys. It is one of the key components of the RPL23 complex.

Potential Drug Target

Rpl23P6 has generated a lot of interest as a potential drug target due to its involvement in the repair of damaged DNA in the cell. One of the ways that Rpl23P6 could be targeted as a drug is by inhibiting its activity as a protein. There are several potential strategies that could be used to achieve this goal.

One approach that could be used to inhibit Rpl23P6's activity is by using small molecules that bind to specific interacting regions of the protein. This would involve using drugs that are able to interfere with the interactions between Rpl23P6 and its interacting partners. There are several examples of small molecules that have been shown to be effective in inhibiting the activity of Rpl23P6.

Another approach that could be used to inhibit Rpl23P6's activity is by using antibodies that are able to bind to specific regions of the protein. This would involve using antibodies that are able to interfere with the interactions between Rpl23P6 and its interacting partners. There are several examples of antibodies that have been shown to be effective in inhibiting the activity of Rpl23P6.

Finally, it is also possible to inhibit Rpl23P6's activity by using drugs that alter its structure. This could involve using drugs that are able to alter the conformation of Rpl23P6, which would prevent it from interacting with its interacting partners. There are several examples of drugs that have been shown to be effective in inhibiting the activity of Rpl23P6.

Conclusion

Rpl23P6 (RPL23_1_689) is a protein that is involved in the repair of damaged DNA in the cell. It is one of the key components of the Replication Protein 23 (RPL23) complex, and has been shown to play a role in the development and progression of various diseases. As a result, Rpl23P6 has generated a lot of interest as a potential drug target or biomarker.

Currently, there are several potential strategies that could be used to inhibit

Protein Name: Ribosomal Protein L23 Pseudogene 6

The "RPL23P6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL23P6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets